Try our Advanced Search for more refined results
Life Sciences - July, 2020
362 articles
- Humana Hits St. Jude With Fresh Suit Over Pacemakers
- Probiotic Drug Cos. In Contempt For Violating Ad Injunction
- Nev. Tax Agency Faces Heat Over Pot Licensing Settlements
- House Panel Says Gov't Overpaid $500M For Ventilators
- Nats Catcher Can't Block His 80-Game Drug Use Suspension
- Stanford Scholar Alleged To Be Chinese Agent Wins Bail
- Teva Gets Fed. Circ. To Affirm Thyroid Patent Is Indefinite
- Valeant Pharma Settles SEC Accounting Probe For $45M
- HHS Can Cut Billions In Payments To Hospitals, DC Circ. Says
- Takeda Loses Appeal To Stop Mylan's Generic Gout Drug
- Ag Industry Wants 9th Circ. To Revisit Dicamba Rescissions
- Gov't Contracts Of The Month: Vaccines, Jets And Sanctions
- J&J Fights ERISA Suit Over Asbestos In Talcum Powder
- Alice-Axed Bovine Breeding Patent Revived At Fed. Circ.
- Market Rebound May Curb Securities Class Actions, Damages
- Out-Of-State Claims Dropped In Calif. Heart Drug Suit
- Fed. Circ.'s UT Immunity Ruling Places Licensing In Spotlight
- Glancy Prongay Seeks $18.2M In Zimmer Biomet Settlement
- Health Hires: McDermott, Goodwin, Gordon Rees
- ABA Must Seize Opportunity To Respond To Bar Exam Chaos
- Hemp Cos. Should Narrow Filings After TTAB's Stanley Ruling
- Surveying Drug Pricing Reform: The Latest Federal Activity
- Major Merger Review Moments From The 1st Half Of 2020
- 3 Developments As New Virus Deaths Continue Summer Spike
- Sanofi And GSK Face DOJ Probes Over Zantac Cancer Risk
- Bayer Antitrust Judge Fears Opening Discovery 'Floodgates'
- Irell Transactions Co-Chair Joins Reed Smith Amid Shift
- Chinese National Admits Trade Secret Theft From Ohio Lab
- Justices Told Horizon's IP Loss 'Casts A Pall' On 32K Patents
- Ex-Lawmaker Sentenced To 2 Years In Pot Bribery Scheme
- Disbarred NY Attys Settle SEC's PixarBio Merger Suit
- Skadden-Led Electric SUV Maker Leads 2 IPOs Totaling $1.3B
- FDA Warns Sellers About Unapproved Hangover Remedies
- Pfizer Biopharma JV To Go Public In $780M SPAC Union
- Humira Buyers Take AbbVie Antitrust Challenge To 7th Circ.
- PTAB Axes Antecip IP, Rejects Its Printed Publication Stance
- Colgate Can't Tweak Retirement Plan To Fight ERISA Suit
- Juul Seeks FDA Approval To Market E-Cigarettes
- How Pandemic Is Affecting The Pace Of Judicial Opinions
- COVID-19 And Design Defect Jurors' Risk Evaluations: Part 3
- Biogen Can't Block Mylan MS Drug Launch During IP Appeal
- Trade Secret Litigation Is Poised To Take Off Amid Downturn
- HIV Drug Suit Against Gilead, BMS And Janssen Trimmed
- GAO Says Most Of $17.8B In COVID-19 Deals Not Competitive
- Delaware Court Denies Medical Pot Coverage Over Work Injury
- Abbott Labs Can't Ditch Cybersecurity Suit, Worker Says
- Stericycle Shareholder Fights $11M Atty Fee Award At 7th Circ.
- Herbalife Distributors Lose Appeal To Arbitrate $1B RICO Row
- Full Fed. Circ. Won't Rehear Actelion Spinoff's Patent Term Bid
- J&J Can't Get Missouri Court To Reconsider $2.1B Talc Ruling
- COVID-19 And Design Defect Jurors' Risk Evaluations: Part 2
- Investors Inject $257M Into Early Cancer Detection Co.
- Allergan Says Proposed Class Rep Is 'Serial Litigant'
- 3 Firms Drive Go-Private Deal Valuing Italy's IMA At €3B
- 6 Steps For Law Firms Looking To Improve Their Culture
- 6th Circ. Questions Opioid Negotiation Class 'Inventiveness'
- Ex-Workers Say Quest 'Asleep At The Wheel' With 401(k) Plan
- Feds Urge Justices To Eye Dozens Of Post-Arthrex Cases
- Hand Sanitizer Can't Kill 99.99% Of Germs, Suit Says
- Brown Rudnick Can't Duck $300M Malpractice Suit
- DEA Can't Keep 9th Circ. Out Of Pot Study Fight, Doctor Says
- Coronavirus Regulations: A State-By-State Week In Review
- 3rd Circ. Affirms Class Cert. In Suboxone Antitrust Case
- Sen. Graham Pushes Tax Break Bill For PPE Repatriation
- COVID-19 And Design Defect Jurors' Risk Evaluations: Part 1
- Pharma Co. Buys CBD Wellness Brand In $20M Deal
- Sanofi, Consultant Must Face Race, Age Bias Claims In NJ
- Virtual Courts Amplify Lawyers' Corporate Spokesperson Role
- 'Pharma Bro' Blasts FTC Monopoly Suit As Overreach
- Numerosity Analysis Fix Can Improve Class Cert. Decisions
- Bayer Wants Shareholder Suit Separate From Roundup MDL
- Life Sciences Co. Grabs $110M In Series C1 Funding Round
- Radish Paste Is Not A COVID-19 Cure, LA City Atty Says
- Gilead Slams HHS' 'Perverse' Requests In HIV Drug IP Battle
- Nats Catcher Says MLB Uses 'Junk Science' Drug Tests
- Pharma Co. Wants Testosterone Drug Investor Suit Tossed
- Whistleblower, Feds Object To Sanctions In Kickback Row
- Senate GOP Unveils $1T Virus Relief Package
- FTC, AbbVie Don't Want Spat Paused Amid Justices' Review
- Garmin Says Cyberattack Knocked Fitness Trackers Offline
- 6 Firms Steer Blank-Check Co.'s $255M Deal With Pot Grower
- Heart Device Co. Investors Sue In Chancery Over Lowball Sale
- Biotech Firm Hit With Chancery Suit Over Stock Transactions
- Aveo Pharma Escapes Investors' Cancer Drug Stock-Drop Suit
- Opioid MDL Judge Won't Set Up $3B Fund For Plaintiffs' Attys
- Full Fed. Circ. Won't Revisit 'Alarming' Relistor Ruling
- Law Firms Must Note Pandemic's Outsize Impact On Women
- Trump's 'Sweeping' Drug Pricing Orders Draw Fury, Doubts
- COVID-19 Vaccine Hacking May Prompt Data Security Rethink
- 2 Firms Guide Coronavirus Vaccine Contender's US IPO Plans
- Judge Advises Freeing Amgen, Teva From Suits Over Sensipar
- 9th Circ. Kills Challenge To Calif. Pay-For-Delay Law
- Convicted Ariad Inside Trader Won't Have To Pay SEC
- AbbVie Sues To Block Dr. Reddy's Generic Leukemia Drug
- Coronavirus Q&A: Sidley Austin's FDA Group Leader
- Fed. Circ. Says UT's Immunity Can't Halt Cancer Patent Suit
- Real Estate Rumors: Metropolitan, Lincoln, Scion
- Why A Surge In Drug Pricing Litigation Is Unlikely
- Complying With China's New Human Genetic Resources Law
- Aetna Blasts Conformis For Using Patient To Force Coverage
- 7 Firms Steer 4 Upsized Biotech IPOs Raising $773M Total
- The 'Rocket Docket' Show Goes On Despite Setbacks
- Aeterna, Shareholders Reach $6.5M Hormone Drug Deal
- Green Thumb Wins TRO In Arkansas Dispensary License Fight
- Pulling Up Stakes: Hogan Lovells, White & Case, Debevoise
- Indivior To Pay $600M To Settle Suboxone Charges
- Moderna Can't Invalidate Drug-Delivery Composition Patent
- DOJ Gives Antitrust Shield To Big Pharma's Virus Info Sharing
- Serenity Faces Skeptical Judge As IP Trial With Ferring Wraps
- Taro Settles DOJ Price Fixing Charges, Will Pay $205M Penalty
- BASF, Cahill Pay $73M To Settle Claims They Hid Asbestos
- Judge To Wait On Claim Talks Result For Purdue Class Call
- Atty Wants Claims Over Failed $57M Mask Deal Tossed
- GOP Virus Aid Plan Stalls Despite Deal On PPP, Taxes, Checks
- FDA Sends New CBD Guidance To White House Budget Office
- How PTAB Reviews Examiner Errors For IPR Institution
- Lab Strikes $1.2M Deal To End Fight With UnitedHealthcare
- Pandemic Lays Bare The Inequities Inherent In The Bar Exam
- Investors Say 9th Circ. Should OK Doc Bid In Hospital Fight
- Fed. Circ. Rejects Minerva Plea To Abolish Assignor Estoppel
- Insurer Sues To Avoid Liability In Fracking Cos.' Dispute
- Special Master Rips Hagens Berman's Privilege Arguments
- GNC's Bidding Procedures OK'd After Extending Sale Timeline
- $3M Apyx Settlement In Securities Suit Gets Initial OK
- Green Thumb Says Ark. Regulators Ignoring License Rules
- Ex-Theranos CEO Seeks Grand Jury Records, Citing COVID-19
- Understanding The 5 Stages Of Mediation In A Virtual World
- Biotech Co. Must Face Securities Suit Over FDA Rejection
- Goulston Seals Tricky Loan For $700M Mass. Turnpike Project
- Novartis Whistleblower Scores $109M For Flagging Kickbacks
- Coronavirus Q&A: Baker Donelson Health Care Chairs
- ITC To Probe German-Made Eye Shot Imports For Infringement
- Pfizer Inks $1.95B Deal To Provide COVID-19 Vaccine Doses
- Trump Shifts Tone On Pandemic, Wishes Well To Epstein's Ex
- Namenda Buyers Want Cert. In Pay-For-Delay Fight
- Ariz. Residents Seek To Block Legal Pot Measure From Ballot
- Pa. Justices Revive Testimony Over Cancer-Pesticide Link
- Coronavirus Regulations: A State-By-State Week In Review
- FDA Issues Guidance For Researchers Working With Cannabis
- Dicamba Makers Ask 9th Circ. To Rehear Nixed Approvals
- 3 Firms Steer Gilead's $300M Purchase Of Cancer Biz Stake
- Pandemic May Change The Way We Design Our Courthouses
- PE Co. Says Travelers Still Dodging Coverage Of Heparin Deal
- Snap Removal Still A Good Option For Defendants — For Now
- Pay-For-Delay May Need More Evidence After 3rd Circ. Ruling
- Elanco Investor Taps Glancy Prongay To Lead Class Dispute
- Pet Products Maker Wants Online Sales Antitrust Suit Tossed
- 2 Chinese Nationals Accused Of Hacking COVID-19 Research
- CVS, Walgreens Want Out Of Blood Pressure Drug MDL
- Opioid Judge 'Concerned' About Amerisource Hiding Docs
- Blood Testing Device Co. Notches Win In Rival's False Ad Suit
- Feds Open Probe Into Imported Handheld Massage Guns
- Monsanto Loses Cancer Liability Fight In 1st Roundup Appeal
- Cannabis Regs: Mass. Floats Sweeping Update To Rules
- Theranos Judge Says Ex-CEO's Oct. Trial Date Is 'Unrealistic'
- Commerce Sets Duties On Plastic From Oman And S. Korea
- Tax Software Co. Vertex Leads 5 IPO Launches Totaling $843M
- UK Reopens Pharma Probes After COVID-19 Delays
- Mediator Confidentiality Promises Carry Serious Risks
- CureVac Scores $296M In GlaxoSmithKline Partnership
- COVID-19 IP Catch-Up: Delays, Masks & Ducks
- Tribes Say Feds Can't Dodge 'Bad Men' Opioids Suit
- To Bring Pharma Onshore, Biden Takes Aim At TCJA
- Cannabis Bill Roundup: Mo. Medical Pot Regime Takes Shape
- Perrigo Investors Can't Get Irish Tax Info For Suit
- GNC Creditors Say Ch. 11 Sale Process Moving Too Quickly
- 3rd Circ. Tosses 'Pay-To-Play' Suit Against Siemens
- How A Compliance Chief Went From Ignored To Whistleblower
- Product Liability Cases To Watch In 2020: Midyear Review
- BakerHostetler Can't Ax Suit Over Ex-Clients' Illegal Gains
- Six Firms Steer Four Health-Focused IPOs Totaling $549M
- Calif. Pay-For-Delay Law Lacks Nuance
- Brand Battles: Allergan Raises Eyebrow Over Botox TM
- The Major Antitrust Conduct Cases Of 2020 So Far
- Why FTC Needs High Court Win On Monetary Equitable Relief
- Rare Disease Biotech Nabs $400M In Financing
- PBM Group Loses Bid To Halt Okla. Law Pending Appeal
- Dreamers Bring Important Perspective To Legal Industry
- SmileDirect Loses Calif. Dental Board Antitrust Suit
- A Big Prop 65 Victory For Chemical Industry In Monsanto Case
- Gilead Tries To Shake Antitrust Suit Over Expensive HIV Drugs
- House Panel Asks Agencies To Explain COVID-19 Contracts
- Thermo Fisher Sweetens Qiagen Takeover Bid To $12.5B
- Purdue Asks Court To Say No To New Classes In Ch. 11 Case
- Pfizer, Mylan Push To Pare Down EpiPen Class Action
- 9th Circ. Skeptical Calif. Pay-For-Delay Law Poses Danger
- Okla. Pharmacy Board Fines CVS $125K For Understaffing
- These 10 Decisions Remade The Patent Landscape
- Poseida Therapeutics Taps Ex-Halozyme Atty As GC
- 6th Circ. Again Refuses To Boot Judge From Opioid MDL
- Biggest Illinois Decisions So Far In 2020: Midyear Report
- Helping Clients Overcome Financial Hurdles Mid-Litigation
- Covidien Asks 1st Circ. To Hand It Ex-Worker's Device Patents
- Convicted Ex-CEO's New Trial Bid Meets Skeptical Judge
- Serenity Expert Defends IP As Zoom Trial Testimony Wraps
- Pfizer Must Face Claims It Didn't Monitor Chantix Risks
- Fired Pot Co. Accountant Says She Had Duty To Report Error
- 5th Circ. Upholds Dallas Pill Mill Operators' Sentences
- Inclusivity Considerations For Law Firms Reopening Offices
- Prepare For DOJ's Pandemic-Related Enforcement Priorities
- C4 Therapeutics Hires Ex-Neon Atty As Legal Chief
- Elanco Divestitures Secure FTC OK For $7.6B Bayer Unit Buy
- Return-To-Work Tech Brings New Contract Issues
- COVID-19 Disruption Reshapes NJ Supply Chains
- How USPTO Examiner Type Affects Patents: Part 3
- PBM Group Goes After Rest Of Okla. Law After Partial Win
- Michael Best Builds Health Care Team With Trio From Humana
- Infringement Has Judge's Eye In Ferring-Serenity Remote Trial
- Fed. Circ. Upholds Dana-Farber's IP Inventorship Victory
- Insys Shareholders Ink Deal With Ex-CEO Over Fraud Claims
- Fed. Circ. Affirms Greatbatch's $22M Pacemaker Patent Win
- Clashes Erupt Nationwide Over High Court's Abortion Ruling
- FTC, Surescripts Debate Liu's Impact On Monopolization Case
- Pot-Focused REIT To Lease $5.5M NJ Property To Curaleaf
- Dispute Over Restitution Power Threatens FTC Antitrust Tool
- BCBS Says Generic Xyrem Delay Was Antitrust Scheme
- Tax Partner Exits Greenspoon Marder With Landmark Pot Suit
- In Their Words: Why Diversity At The Bar Is Still A Problem
- The Year's Top High Court Moments From Law360's The Term
- Improper Testimony Won Pa. Mesh Case For J&J, Panel Told
- Surprising Alliances Shape The Supreme Court Term
- 11th Circ. Again Affirms Atty's Stock Fraud Conviction
- Fla. High Court Orders More Arguments On Pot License Law
- States' Case To Be Bellwether In Generic Drug Price-Fix MDL
- 5th Circ. Upholds $905K Verdict In Diagnostic Lab Spat
- Coronavirus Regulations: A State-By-State Week In Review
- How Cosmetics Cos. Can Prepare For Growth In Class Actions
- UK Eyeing Conditions On Stryker's $4B Wright Medical Deal
- Biopharmaceutical Co. Raises $250M From RTW Investments
- Mesh Case Judge Tainted By His Mom's J&J Suit, Court Told
- FinCEN Guidance A Positive Step For Hemp Businesses
- Nektar Dodges Stock-Drop Suit Over Poor Study Results
- Aspen Offers To Slash Prices On Cancer Drugs In EU Probe
- Why Can't Female Lawyers Make Headway At The High Court?
- NY High Court Case Could Upend Litigation Finance Industry
- Law360's Supreme Court Pop Quiz
- Ex-Ferring Exec Says He Had Rival's Drug Innovation First
- Pot Tracking Service Says It Can Charge Mo. Stores Fees
- 'Unfounded Attacks' On Opioid Judge Must Fail, 6th Circ. Told
- 3rd Circ. Mulling FTC-AbbVie Pause Till High Court Acts
- 2nd Circ. Revives NewLink Investor Suit Over Cancer Drug
- The Sharpest Dissents From The Supreme Court Term
- Perrigo Investors Push For Class Action Over Irish Tax Audit
- SmileDirect Likely To Lose Calif. Dental Antitrust Suit
- 5 Compliance Lessons From Novartis' FCPA Settlement
- Six Firms Steer Five IPO Launches That Could Raise $501M
- Associates Can Prioritize Biz Development Despite Pandemic
- Mallinckrodt Aims To Nix Medicaid FCA Suit Over Acthar Gel
- Feds And Eye Product Co. Sanctioned In Kickback Suit
- The Funniest Moments Of The Supreme Court's Term
- The Chattiest Justice Of The Term Is ...
- Restasis Buyers Seek $16M Atty Fees In Antitrust Case
- Judge Boots Klamann Law Firm From DST 401(k) Plan Suit
- Should Cos. Use USPTO's New Fast-Track Appeals Program?
- Attys Should Stop Using 2 Common Cannabis Industry Terms
- Client Says Hagen Berman Pulled Fast One On Special Master
- Bitter Neighbor Sank Farm's Shot At Pot License, Suit Claims
- 11th Circ. Affirms Bulk Of Ala. Doctors' 'Pill Mill' Convictions
- COVID-19 IP Catch-Up: NY Trial Finally Starts, Texas Holds Off
- The Majority Of One: How Roberts Is Shaping The Court
- FDA To Restart On-Site Inspections Paused For Virus
- Judge 'Taken Aback' By Vivus Equity Tradeoff In Ch. 11
- Breaking Down The Vote: The High Court Term In Review
- The Firms That Won Big At The Supreme Court
- Zimmer Injury Suit Stayed During Settlement Talks
- Rite Aid Accuses 47 Generic Makers Of Price-Fixing
- 6 Firms Steer Trio Of Biotech IPOs Totaling $584M
- DuPont Will Pay $3.4M To End Texas Hazardous Waste Suit
- Let's Create An Ethical Obligation For Attys To Fight Racism
- Miss. Businessman Pleads Guilty To $288M Tricare Fraud
- New Pharma Co. Defenses For 'Innovator Liability' Claims
- AbbVie Faces Suit Over Delays In Generic Blood Pressure Med
- Possibilities If Justices Review PTAB Judge Constitutionality
- Deals On Blistering Pace In 2020 Even As Virus Fears Linger
- UK Litigation Roundup: Here's What You Missed In London
- Justices Told PTAB Constitutional Issues Persist Post-Arthrex
- Full Fed. Circ. Won't Consider Standing In Novartis Drug Case
- Ferring Experts Attack Serenity Patents In SDNY Zoom Trial
- NuVasive Spinal Fusion Patents Largely Survive PTAB Review
- 1st Circ. Affirms Pharmacists' Guilt In Meningitis Outbreak
- Feds Indict 4 In Alleged $34M Pharma Kickback Scheme
- Shearman & Sterling Taps Bird & Bird Int'l Arbitration Atty
- Patent Cases To Watch In The Second Half Of 2020
- Acreage Subsidiary To Pay $250K Fine To Mass. Pot Board
- 3rd Circ. Won't Revive NJ Doc's Suit Over Improper Training
- Mass. Pot Board Fines Cos. $550K Over Pesticide Violations
- Walgreens Wants Insurers' Overcharging Suit Tossed
- A Look At CMS' Proposed Medicaid Drug Rebate Changes
- Fed. Circ. Patent Eligibility Test Erroneously Distorts Alice
- Teva Says Securities Claims Filed Too Late In Price-Fixing Suit
- Merck Spinoff Organon Hires Ex-Sorrento, Abbott Atty As GC
- 6 Considerations When Shopping For Legal Tech Software
- Blank Check Co.'s Goodwin-Led $118M IPO Employs Odd Tact
- 'What About Federalism?' Judge Asks In 11th Circ. Dental Suit
- Ohio Ruling Adds To Insurance Uncertainty For Opioid Suits
- FTC Says Online Retailer Lied About PPE Shipping Speeds
- Wholesaler Dropped As Lead In ADHD Drug Antitrust Suit
- K&L Gates Nabs Health Care Partner From Morgan Lewis
- Group To Revise Deal For Future Claims In Monsanto MDL
- Law Firm Strategies For Publicizing Laterals Amid Lockdowns
- Bull Semen Co. Wants $5M In Fees From Antitrust Trial Win
- Bias Charge Is 'Dangerous Fiction,' Opioid MDL Judge Says
- Serenity Says Ferring Owes $389K In SDNY Zoom IP Trial
- Pharma Exec Wants Out Of Hemp Co. Shareholder Suit
- Pot Co. Accuses Pryor Cashman Of Airing Confidential Deal
- Pharma Co. Files Ch. 11 Plan Proposing Icahn Acquisition
- Botox Maker Wins First Phase Of Rival Import Investigation
- FTC Fights Shkreli's Bid To Duck Monopolization Case
- Merck, Glenmark Implore Court To Reject Zetia Class Cert.
- Bid Protest Spotlight: Limitations, Timeliness, Cost-Realism
- Judge Finds No Fraud In Vote For Melinta's Ch. 11 Plan
- Faegre Drinker Guides Medical Device Biz's $50M Financing
- Are Your Slack Communications Primed For E-Discovery?
- Judge 'Skeptical' Of Settlement For Future Roundup Claims
- Amerisource Tries To Save CEO From Opioid Bellwether Depo
- Coronavirus Regulations: A State-By-State Week In Review
- Novavax Wins $1.6B From Feds To Make COVID-19 Vaccine
- Sanofi Urges High Court To Expand Arthrex To All
- Pharma Tech Co. Asks To End Suit Against Hemp Consultant
- Generics' Bid To Limit IP Loss 'Makes No Sense,' Judge Says
- Ferring And Serenity's SDNY Patent Trial Kicks Off Over Zoom
- Cooley Steers 2 Biotechs Planning Combined $252M In IPOs
- Hogan Lovells Nabs Ex-Bristol Myers Squibb Associate GC
- Fed. Circ. Clears Amgen's Avastin Biosimilar In Notice Fight
- Digital Education Provider Joins July's Growing IPO Pipeline
- How Therapeutic Formulations Affect Medical Device Patents
- Seattle Concerned About Bayer's $820M PCB Settlements
- 6 Dispute Prevention Steps As Lawsuits Rise Amid Pandemic
- Pharmacies Can't Slip Opioid Nuisance Claims, Counties Say
- Blaszczak Ruling's Broad View Of Property May Trouble Press
- Law360 Names Top Attorneys Under 40
- Portola Says Stock Drop Was 'Reversal Of Fortune,' Not Fraud
- GSK Takes Avandia Marketing Battle To Supreme Court
- J&J Investors Seek Cert. In Asbestos Stock-Drop Suit
- As Courts Punt CBD Class Actions, Attys Wait For FDA To Act
- Entrepreneur Who Gave Tips On Dad's Pharma Co. Gets Year
- Top Delaware Cases Of 2020: A Midyear Report
- Top New Jersey Cases Of 2020: A Midyear Report
- Don't Count On PREP Act To Defend Pandemic IP Infringement
- Biotech Firms Drive IPO Rebound While 'Unicorns' Gear Up
- Gov't Contracts Of The Month: Vaccine, Radars, Submarines
- Time To Consider Percentage Rental Agreements For Lawyers
- Indirect Purchaser Antitrust Standing Heads In New Direction
- Alexion Pharmaceuticals To Pay SEC $21M Over FCPA Claims
- Novartis To Pay $729M To End 2 FCA Kickback Accusations
- Insys Execs Can't Dodge Prison During Appeal, Seek Delay
- Cook Chastises Firm For 'No-Injury' Vein Filter Bellwether
- Akorn Gets Del. Ch. 11 Disclosure OK As Plan Fight Looms
- Fed. Circ. Keeps Sandoz's Enbrel Biosimilar Off The Market
- Agendia Pays $8.25M In FCA Suit Over Delayed Cancer Tests
- Fed. Circ., Judge Nix CardioNet Heart Monitor Patent Claims
- Abbott Labs Tries To Shake ERISA Cybersecurity Suit
- Gannett Hit With $500M Libel Suit Over Antibody Test Story
- Sandoz Dodges Sanctions Bid In Antitrust Dispute
- Bausch Not Covered For Allergan Case, Insurers Say
- Portola Investor Wants Docs About $1.4B Alexion Deal
- Annexon Raises $100M To Push Autoimmune, Brain Therapies
- Indivior Wants 3rd Circ. To Undo Suboxone Class Cert.
- Skadden-Led SPAC Prices $125M IPO To Fund Biotech Buy
- Canadian Pharma Co. Wants Investors' Stock-Drop Suit Nixed
- 'Settle And Sue' Malpractice Cases Have New Clarity In Calif.
- Block & Leviton Tapped To Lead Biopharma Stock-Drop Suit